Work

PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-150852

Authors: Kristie A. Blum, Jeffrey G. Supko, Michael Maris, Ian W. Flinn, Andre H. Goy, Anas Younes, Suresh Bobba, Adrian Senderowicz, Sergey Efuni, Ronda Rippley, Jeremy S. Abramson

Institutions: Emory University, Winship Cancer Institute, Massachusetts General Hospital, Colorado Blood Cancer Institute, Sarah Cannon, Hackensack University Medical Center, Memorial Sloan Kettering Cancer Center, Constellation Pharmaceuticals (United States)

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3213346393

Cites:

Cited by: 3

Related to: 10